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Guest Editorial
South African guidelines for the treatment of cancer pain:  
South African Cancer Pain Guidelines Working Group 
The production of these guidelines, written by South African 
medical practitioners, is a most welcome and important step 
in the treatment of cancer pain in this country. The overall 
prevalence of pain in cancer patients is estimated to be 53%, 
and 64% in patients with advanced and metastatic disease.1 Too 
often, the only guidelines available to us are those written by 
practitioners in other countries which may be inappropriate for 
implementation here owing to the differing availability of drugs 
or disease profile. 
The reproducibility of information is important in the South 
African situation. The direct, simple language used in these 
guidelines will facilitate ease of translation into different 
languages e.g. isiZulu, Xhosa and Afrikaans. The clear and 
precisely illustrated flow diagrams lend themselves to being 
reproduced in the form of charts and posters, which would be 
useful when disseminating this information at district hospitals 
and community clinics. These well thought out guidelines 
provide the first vital step in appropriate pain management to 
cancer and other terminally ill patients. The next step is education 
of healthcare practitioners at all levels, and the implementation 
of the guideline to improve the lives of patients afflicted with 
life-threatening diseases. With the use of multiple acronyms 
[precipitating factors, quality of symptom, relieving factors, 
severity and temporal relationship (PQRST) and (quit smoking, 
understand your body and get checked, eat healthily and drink 
less alcohol, stay sun smart every day and take time to be active 
(QUESTT)] and flow charts, it appears that the authors intended 
this when preparing this document. 
The stepwise healthcare intervention for pain approach that the 
working group has devised involves a comprehensive review 
of the pharmacological treatment of pain for both children 
and adults. Other vital issues, such as pain assessment and 
the nonpharmacological treatment of pain, are covered. It is 
correctly stated at the outset that pain management should 
be multidisciplinary, and the role of psychological therapies, 
physiotherapy, occupational therapy, spirituality and other 
complementary therapies at every step is emphasised. The 
practical pharmacological guideline for children is especially 
important, since historically “opiophobia” has resulted in many 
suffering paediatric (and adult) patients being denied adequate 
analgesia. 
The adopted format is the 1996 World Health Organization 
cancer pain relief guidelines, which, while commonplace in 
similar oncology treatment guides, are not without criticism. 
Sound treatment principles are proposed, i.e. that preferably, 
analgesia should be administered orally, i.e. “by the mouth”, that 
it should be administered at regular intervals, i.e. “by the clock”, 
and that medication should be administered in incremental 
steps of increasing potency, i.e. “by the ladder”.2 If we aim to 
achieve just these seemingly basic steps in the next few years, 
we will have been very successful indeed. 
A few important aspects of pain management were not discussed, 
and these concern codeine, tramadol and methadone. The use 
of codeine is contentious internationally. As pointed out in the 
guidelines, it requires being metabloised to morphine in order 
to act as an analgesic, but 5-10% of patients lack the enzyme 
required for this conversion [cytochrome P450 (CYP) 2D6] and 
may receive insufficient analgesia with codeine. Conversely, 
1-2% of patients (this rate is higher in some ethnic groups, 
e.g. 6% in Greeks3 and 29% in Ethiopians4) may be ultra-rapid 
metabolisers of codeine, and the rapid conversion of codeine 
to morphine in these patients renders them at risk of sudden 
respiratory depression.5 Following case reports of deaths in 
children from this occurrence, there are some institutions (e.g. 
Toronto’s Hospital for Sick Children) in which codeine is not used, 
and only morphine given, as its effects are more predictable.6 
These guidelines follow this approach and omit the use of 
codeine in children with cancer pain. Caution is still warranted 
with regard to codeine use in adults, and it should be avoided 
in breastfeeding mothers7 (unless CYP2D6 testing can be carried 
out, which is not routinely available in most public hospitals) and 
in the ethnic groups associated with ultra-fast metabolism.
The availability of codeine in South African public hospitals is 
another challenge. Codeine is not listed for the treatment of pain 
in the current adult hospital level standard treatment guidelines 
(STGs), and there is a possibility that it may be removed in the 
next edition of primary healthcare STGs. In future, drugs that are 
not in the Department of Health STGs will not be readily available 
in South African public institutions, and may include codeine. 
Several other drugs are also recommended in the guidelines 
for the treatment of cancer pain which are not in the STGs 
(e.g. oxycodone, hydromorphone and transdermal fentanyl). The 
authors of these guidelines should consider motivating for these 
drugs to be included in the STGs so that they can be available in 
South African public hospitals. 
Tramadol warrants its inclusion in these guidelines as it is both 
available (it is in the adult hospital level STGs) and effective. 
Unfortunately, it is not without side-effects, and while these 
are briefly mentioned in the guidelines, its association with the 
serotonin syndrome is not included. There is a real possibility 
of precipitating this potentially life-threatening condition 
with chronic, high-dose tramadol use, particularly if given to 
cancer pain patients who are concomitantly receiving other 
drugs which increase intrasynaptic serotonin, e.g. amitriptyline 
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(doses up to 150 mg are recommended in these guidelines for 
the treatment of neuropathic pain). Those prescribing tramadol 
must be aware of the possibility of this syndrome, especially if 
patients start complaining of symptoms relating to the classical 
clinical triad of mental state changes, autonomic hyperactivity 
and neuromuscular hyperactivity.8
Opioid-induced hyperalgesia (increasing pain sensitivity in 
patients chronically exposed to opioids without any evidence 
of new causes of pain9) is an important condition relevant to 
the treatment of cancer pain with high-dose opioids, which 
is not discussed in the guidelines. Increasing morphine doses 
paradoxically result in escalating pain in opioid-induced 
hyperalgesia. There is evidence that this unpleasant scenario 
can be reversed by switching to methadone, but unfortunately, 
few practitioners in South Africa are experienced in the use of 
methadone for the treatment of pain, and methadone is certainly 
not without its problems. Careful dose titration is required, and 
there is the risk of accumulation. However, methadone has 
advantages too. It is relatively inexpensive and it may only need 
to be given once daily because of its long half-life. Its onset is 
also rapid. There is growing international experience of the use 
of methadone to manage cancer pain, even in an outpatient 
setting,10 and it should certainly be considered in patients with 
opioid-induced hyperalgesia or in other difficult-to-manage 
cases.11
The spectrum of patients with cancer pain ranges from 
survivors living with chronic pain, to patients who have pain 
due to both cancer and non-cancer-related disease processes, 
e.g. chemotherapy and radiotherapy treatments, and 
procedure-related pain, as well as those requiring end-of-life 
care. The quality of life of patients with chronic pain can be 
improved by optimising both nociceptive and neuropathic 
analgesia. Neuropathic pain may arise from radiation-induced 
neuritis, chemotherapy-induced peripheral neuropathy or as 
a paraneoplastic phenomenon. Many cancer pain guidelines 
only describe the treatment of nociceptive pain, so it is of 
value that these guidelines clearly describe not only how to 
identify neuropathic pain, but also how to treat it. However, 
insufficient clinical trials have addressed the pharmacological 
treatment of neuropathic pain in cancer patients so evidence-
based guidelines for this condition have not been provided. The 
treatment given is largely based on evidence obtained from 
studies on neuropathic pain arising from other conditions, and 
further studies are required to validate their use in neuropathic 
cancer pain. In addition to the drugs included in the guidelines, 
it is worth noting that the use of topical 5% lignocaine and 8% 
capsaicin has shown promise. Capsaicin depletes substance 
P via the transient receptor potential vanilloid receptor 1, and 
has demonstrated modest reductions in pain scores for up to 
12 weeks in patients with painful polyneuropathy and posther-
petic neuralgia.12
A discussion on the treatment of cancer pain with opiates is 
incomplete without consideration being given to the effect of 
opioids on survival from cancer. While the guidelines do not 
touch on this subject, it is worth bringing to the attention of 
practitioners that currently, growing evidence suggests that 
using opioids to treat cancer pain reduces survival.13 How this 
impacts on the future use of opioids in patients with cancer pain 
remains to be seen. Practitioners should consider non-opioid 
analgesics where possible, but at present, should not completely 
stop using opioids for cancer pain as quality of life is as important 
as its duration.
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